How to buy Beam Therapeutics stock | 36.88

Beam Therapeutics Inc is a biotechnology business based in the US. Beam Therapeutics shares (BEAM) are listed on the NASDAQ and all prices are listed in US Dollars. Beam Therapeutics employs 151 staff and has a trailing 12-month revenue of around USD$24,000.

How to buy shares in Beam Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Beam Therapeutics. Find the stock by name or ticker symbol: BEAM. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Beam Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$36.88, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Beam Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Beam Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Beam Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Beam Therapeutics's share price has had significant positive movement.

Its last market close was USD$36.88, which is 29.26% up on its pre-crash value of USD$26.09 and 183.69% up on the lowest point reached during the March crash when the shares fell as low as USD$13.

If you had bought USD$1,000 worth of Beam Therapeutics shares at the start of February 2020, those shares would have been worth USD$inf at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$inf.

Beam Therapeutics share price

Use our graph to track the performance of BEAM stocks over time.

Beam Therapeutics shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	USD$36.88
52-week range	USD$13 - USD$34.38
50-day moving average	USD$26.9746
200-day moving average	USD$23.7798
Wall St. target price	USD$32
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-2.0086

Buy Beam Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Beam Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Beam Therapeutics Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Beam Therapeutics price performance over time

Historical closes compared with the close of $36.88 from 2020-11-16

1 week (2020-11-17)	-3.68%
1 month (2020-10-23)	-2.67%
3 months (2020-08-24)	43.73%
6 months (2020-05-22)	43.95%

1 year (2019-11-20)	N/A
2 years (2018-11-20)	N/A
3 years (2017-11-20)	N/A
5 years (2015-11-20)	N/A

Beam Therapeutics financials

Revenue TTM	USD$24,000
Gross profit TTM	USD$18,000
Return on assets TTM	-25.76%
Return on equity TTM	-59.57%
Profit margin	0%
Book value	$4.649
Market capitalisation	USD$1.8 billion

TTM: trailing 12 months

Shorting Beam Therapeutics shares

There are currently 3.6 million Beam Therapeutics shares held short by investors – that's known as Beam Therapeutics's "short interest". This figure is 8.7% up from 3.3 million last month.

There are a few different ways that this level of interest in shorting Beam Therapeutics shares can be evaluated.

Beam Therapeutics's "short interest ratio" (SIR)

Beam Therapeutics's "short interest ratio" (SIR) is the quantity of Beam Therapeutics shares currently shorted divided by the average quantity of Beam Therapeutics shares traded daily (recently around 520850.28653295). Beam Therapeutics's SIR currently stands at 6.98. In other words for every 100,000 Beam Therapeutics shares traded daily on the market, roughly 6980 shares are currently held short.

However Beam Therapeutics's short interest can also be evaluated against the total number of Beam Therapeutics shares, or, against the total number of tradable Beam Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Beam Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Beam Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.141% of the tradable shares (for every 100,000 tradable Beam Therapeutics shares, roughly 141 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Beam Therapeutics.

Find out more about how you can short Beam Therapeutics stock.

Beam Therapeutics share dividends

We're not expecting Beam Therapeutics to pay a dividend over the next 12 months.

Beam Therapeutics overview

Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.

Frequently asked questions

• What percentage of Beam Therapeutics is owned by insiders or institutions?

  Currently 13.614% of Beam Therapeutics shares are held by insiders and 23.312% by institutions.

• How many people work for Beam Therapeutics?

  Latest data suggests 151 work at Beam Therapeutics.

• When does the fiscal year end for Beam Therapeutics?

  Beam Therapeutics's fiscal year ends in December.

• Where is Beam Therapeutics based?

  Beam Therapeutics's address is: 26 Landsdowne Street, Cambridge, MA, United States, 02139

• What is Beam Therapeutics's CUSIP number?

  Beam Therapeutics's Committee on Uniform Securities Identification Procedures number is: 073730103